Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Neuroblastoma | Research article

Response of neuroblastoma cells to RF currents as a function of the signal frequency

Authors: María Luisa Hernández-Bule, Enrique Medel, Clara Colastra, Raquel Roldán, Alejandro Úbeda

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Capacitive-resistive electric transfer (CRET) is a non-invasive therapeutic strategy that applies radiofrequency electric currents within the 400–600 kHz range to tissue repair and regeneration. Previous studies by our group have shown that 48 h of intermittent exposure to a 570 kHz CRET signal at a subthermal density of 50 μA/mm² causes significant changes in the expression and activation of cell cycle control proteins, leading to cycle arrest in human cancer cell cultures. The present study investigates the relevance of the signal frequency in the response of the human neuroblastoma cell line NB69 to subthermal electric treatment with four different signal frequency currents within the 350–650 kHz range.

Methods

Trypan blue assay, flow cytometry, immunofluorescence and immunoblot were used to study the effects of subthermal CRET currents on cell viability, cell cycle progression and the expression of several marker proteins involved in NB69 cell death and proliferation.

Results

The results reveal that among the frequencies tested, only a 448 kHz signal elicited both proapoptotic and antiproliferative, statistically significant responses. The apoptotic effect would be due, at least in part, to significant changes induced by the 448 kHz signal in the expression of p53, Bax and caspase-3. The cytostatic response was preceded by alterations in the kinetics of the cell cycle and in the expression of proteins p-ERK1/2, cyclin D1 and p27, which is consistent with a potential involvement of the EGF receptor in electrically induced changes in the ERK1/2 pathway. This receives additional support from results indicating that the proapototic and antiproliferative responses to CRET can be transiently blocked when the electric stimulus is applied in the presence of PD98059, a chemical inhibitor of the ERK1/2 pathway.

Conclusion

The understanding of the mechanisms underlying the ability of slowing down cancer cell growth through electrically-induced changes in the expression of proteins involved in the control of cell proliferation and apoptosis might afford new insights in the field of oncology.

Kotnik T, Miklavcic D. Theoretical evaluation of the distributed power dissipation in biological cells exposed to electric fields. Bioelectromagnetics. 2000;21:385–94.PubMedCrossRef

Grimnes S, Martinsen ØG. Joule effect and temperature rise. In: Academic press, editor. Bioimpedance and bioelectricity basics. London: Harcourt and Technology Company; 2000. p. 71–3.

Kumaran B, Watson T. Treatment using 448 kHz capacitive resistive monopolar radiofrequency improves pain and function in patients with osteoarthritis of the knee joint: a randomised controlled trial. Physiotherapy. 2018. https://doi.org/10.1016/j.physio.2018.07.004.PubMedCrossRef

Tashiro Y, Hasegawa S, Yokota Y, Nishiguchi S, Fukutani N, Shirooka H, Tasaka S, Matsushita T, Matsubara K, Nakayama Y, et al. Effect of capacitive and resistive electric transfer on haemoglobin saturation and tissue temperature. Int J Hyperth. 2017. https://doi.org/10.1080/02656736.2017.1289252.PubMedCrossRef

Yokota Y, Sonoda T, Tashiro Y, Suzuki Y, Kajiwara Y, Zeidan H, Nakayama Y, Kawagoe M, Shimoura K, Tatsumi M, et al. Effect of capacitive and resistive electric transfer on changes in muscle flexibility and lumbopelvic alignment after fatiguing exercise. J Phys Ther Sci. 2018. https://doi.org/10.1589/jpts.30.719.PubMedPubMedCentralCrossRef

Bito T, Tashiro Y, Suzuki Y, Kajiwara Y, Zeidan H, Kawagoe M, Sonoda T, Nakayama Y, Yokota Y, Shimoura K, et al. Acute effects of capacitive and resistive electric transfer (CRet) on the Achilles tendon. Electromagn Biol Med. 2019. https://doi.org/10.1080/15368378.2019.1567525.PubMedCrossRef

Ohguri T, Yahara K, Moon SD, Yamaguchi S, Imada H, Terashima H, Korogi Y. Deep regional hyperthermia for the whole thoracic region using 8 MHz radiofrequency- capacitive heating device: relationship between the radiofrequencyoutput power and the intra-oesophageal temperature and predictive factors for a good heating in 59 patients. Int J Hyperth. 2011. https://doi.org/10.3109/02656736.2010.500644.PubMedCrossRef

Ohguri T, Imada H, Yahara K, Moon SD, Yamaguchi S, Yatera K, Mukae H, Hanagiri T, Tanaka F, Korogi Y. Reirradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients. Lung Cancer. 2012. https://doi.org/10.1016/j.lungcan.2012.02.018.PubMedCrossRef

Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013. https://doi.org/10.5732/cjc.013.10177.PubMedPubMedCentralCrossRef

10.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2017.5082.PubMedPubMedCentralCrossRef

11.

Kato S, Asada R, Kageyama K, Saitoh Y, Miwa N. Anticancer effects of 6-o-palmitoyl-ascorbate combined with a capacitive-resistive electric transfer hyperthermic apparatus as compared with ascorbate in relation to ascorbyl radical generation. Cytotechnology. 2011;63:425–35.PubMedPubMedCentralCrossRef

12.

San BH, Moh SH, Kim KK. Investigation of the heating properties of platinum nanoparticles under a radiofrequency current. Int J Hyperth. 2013;29:99–105.CrossRef

13.

Hernandez-Bule ML, Paino CL, Trillo MA, Ubeda A. Electric stimulation at 448 kHz promotes proliferation of human mesenchymal stem cells. Cell Physiol Biochem. 2014. https://doi.org/10.1159/000366375.PubMedCrossRef

14.

Hernandez-Bule ML, Martinez-Botas J, Trillo MA, Paino CL, Ubeda A. Antiadipogenic effects of subthermal electric stimulation at 448 kHz on differentiating human mesenchymal stem cells. Mol Med Rep. 2016;13:3895–903.PubMedPubMedCentralCrossRef

15.

Hernandez-Bule ML, Trillo MA, Martinez-Garcia MA, Abilahoud C, Ubeda A. Chondrogenic differentiation of adipose-derived stem cells by radiofrequency electric stimulation. J Stem Cell Res Ther. 2017. https://doi.org/10.4172/2157-7633.1000407.

16.

Hernandez-Bule ML, Trillo MA, Cid MA, Leal J, Ubeda A. In vitro exposure to 0.57 MHz electric currents exerts cytostatic effects in HepG2 human hepatocarcinoma cells. Int J Oncol. 2007;30:583–92.PubMed

17.

Hernandez-Bule ML, Cid MA, Trillo MA, Leal J, Ubeda A. Cytostatic response of HepG2 to 0.57 MHz electric currents mediated by changes in cell cycle control proteins. Int J Oncol. 2010;37:1399–405.PubMed

18.

Hernandez-Bule ML, Trillo MA, Ubeda A. Molecular mechanisms underlying antiproliferative and differentiating responses of hepatocarcinoma cells to subthermal electric stimulation. PLoS One. 2014. https://doi.org/10.1371/journal.pone.0084636.PubMedPubMedCentralCrossRef

19.

Hernandez-Bule ML, Roldan E, Matilla J, Trillo MA, Ubeda A. Radiofrequency currents exert cytotoxic effects in NB69 human neuroblastoma cells but not in peripheral blood mononuclear cells. Int J Oncol. 2012. https://doi.org/10.3892/ijo.2012.1569.

20.

McNamee P, Chauhan A. Radiofrequency radiation and gene/protein expression: a review. Radiat Res. 2009. https://doi.org/10.1667/RR1726.1.PubMedCrossRef

21.

Taghian T, Narmoneva DA, Kogan AB. Modulation of cell function by electric field: a high-resolution analysis. J R Soc Interface. 2015. https://doi.org/10.1098/rsif.2015.0153.PubMedCentralCrossRef

22.

Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. Targeting the p53 pathway of apoptosis. Curr Pharm Des. 2010;16:2493–503.PubMedCrossRef

23.

Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C, Pearson AD, Lunec J, Tweddle DA. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle. 2007;6:2685–96.PubMedCrossRef

24.

Qi L, Toyoda H, Shankar V, Sakurai N, Amano K, Kihira K, Iwasa T, Deguchi T, Hori H, Azuma E, et al. Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses. Cancer Sci. 2013. https://doi.org/10.1111/cas.12204.PubMedCrossRef

25.

Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 2011;10:57–67.PubMedPubMedCentralCrossRef

26.

Martinelli E, Morgillo F, Troiani T, Ciardiello F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK. Cancer Treat Rev. 2017. https://doi.org/10.1016/j.ctrv.2016.12.001.PubMedCrossRef

27.

Porat Y, Giladi M, Schneiderman RS, Blat R, Shteingauz A, Zeevi E, Munster M, Voloshin T, Kaynan N, Tal O, et al. Determining the optimal inhibitory frequency for cancerous cells using tumor treating fields (TTFields). J Vis Exp. 2017. https://doi.org/10.3791/55820.

28.

Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015. https://doi.org/10.1038/srep18046.

29.

Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Haag P, Bomzon Z, Kirson ED, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017. https://doi.org/10.1186/s13014-017-0941-6.

30.

Buttiglione M, Roca L, Montemurno E, Vitiello F, Capozzi V, Cibelli G. Radiofrequency radiation (900 MHz) induces Egr-1 gene expression and affects cell-cycle control in human neuroblastoma cells. J Cell Physiol. 2007;213:759–67.PubMedCrossRef

31.

Borriello A, Roberto R, Della Ragione F, Iolascon A. Proliferate and survive: cell division cycle and apoptosis in human neuroblastoma. Haematologica. 2002;87:196–214.PubMed

32.

Matt S, Hofmann TG. The DNA damage-induced cell death response: a roadmap to kill cancer cells. Cell Mol Life Sci. 2016. https://doi.org/10.1007/s00018-016-2130-4.PubMedCrossRef

33.

Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94:1313–26.PubMedPubMedCentralCrossRef

34.

Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41–7.PubMedCrossRef

35.

Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26:3227–39.PubMedCrossRef

36.

VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 2015. https://doi.org/10.1158/1078-0432.CCR-14-0816.PubMedCrossRef

37.

Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010. https://doi.org/10.1186/1756-8722-3-8.

38.

Bromberg-White JL, Andersen NJ, Duesbery NS. MEK genomics in development and disease. Brief Funct Genomics. 2012. https://doi.org/10.1093/bfgp/els022.PubMedPubMedCentralCrossRef

39.

Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007;1773:1213–26.PubMedCrossRef

40.

Goodman R, Lin-Ye A, Geddis MS, Wickramaratne PJ, Hodge SE, Pantazatos SP, Blank M, Ambron RT. Extremely low frequency electromagnetic fields activate the ERK cascade, increase hsp70 protein levels and promote regeneration in Planaria. Int J Radiat Biol. 2009. https://doi.org/10.1080/09553000903072488.PubMedPubMedCentralCrossRef

41.

Martinez MA, Ubeda A, Cid MA, Trillo MA. The proliferative response of NB69 human neuroblastoma cells to a 50 Hz magnetic field is mediated by ERK1/2 signaling. Cell Physiol Biochem. 2012. https://doi.org/10.1159/000178457.PubMedCrossRef

42.

Friedman J, Kraus S, Hauptman Y, Schiff Y, Seger R. Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochem J. 2007;405:559–68.PubMedPubMedCentralCrossRef

43.

Artacho-Cordon F, Salinas-Asensio MM, Calvente I, Rios-Arrabal S, Leon J, Roman-Marinetto E, Olea N, Nuñez MI. Could radiotherapy effectiveness be enhanced by electromagnetic field treatment? Int J Mol Sci. 2013. https://doi.org/10.3390/ijms140714974.PubMedCentralCrossRef

44.

Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci. 2006;31:268–75.PubMedCrossRef

45.

Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol. 2007;18:1605–19.PubMedCrossRef

46.

Inaba N, Fujioka K, Saito H, Kimura M, Ikeda K, Inoue Y, Ishizawa S, Manome Y. Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide. Anticancer Res. 2011;31:3253–7.PubMed

47.

Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005;65:9868–75.PubMedCrossRef

48.

Ke XQ, Sun WJ, Lu DQ, Fu YT, Chiang H. 50-Hz magnetic field induces EGF-receptor clustering and activates RAS. Int J Radiat Biol. 2008. https://doi.org/10.1080/09553000801998875.PubMedCrossRef

49.

Park JE, Seo YK, Yoon HH, Kim CW, Park JK, Jeon S. Electromagnetic fields induce neural differentiation of human bone marrow derived mesenchymal stem cells via ROS mediated EGFR activation. Neurochem Int. 2013. https://doi.org/10.1016/j.neuint.2013.02.002.PubMedCrossRef

50.

Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009;5:44–451.PubMedCrossRef

51.

Nolo R, Herbrich S, Rao A, Zweidler-McKay P, Kannan S, Gopalakrishnan V. Targeting P-selectin blocks neuroblastoma growth. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.21364.

52.

Martinez MA, Ubeda A, Moreno J, Trillo MA. Power frequency magnetic fields affect the p38 MAPK-mediated regulation of NB69 cell proliferation implication of free radicals. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17040510.PubMedPubMedCentralCrossRef

53.

Yarza R, Vela S, Solas M, Ramirez MJ. c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease. Front Pharmacol. 2015. https://doi.org/10.3389/fphar.2015.00321.

54.

Bálint E, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer. 2001;85:1813–23.PubMedCentralCrossRef

Title: Response of neuroblastoma cells to RF currents as a function of the signal frequency
Authors: María Luisa Hernández-Bule
Enrique Medel
Clara Colastra
Raquel Roldán
Alejandro Úbeda
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Neuroblastoma
Neuroblastoma
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-6090-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"

Correction to: Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools

Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells

Long-term survival and prognostic factors for locally advanced renal cell carcinoma with renal vein tumor thrombus

Clinical significance of serum PSA in breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer